Related references
Note: Only part of the references are listed.
Article
Pharmacology & Pharmacy
Martina Calusic et al.
Summary: Fluvoxamine, as an early treatment option, has shown promise in preventing COVID-19 progression in three trials. This study evaluated the safety and efficacy of fluvoxamine in COVID-19 patients when administered later in the disease course. The results suggest that fluvoxamine treatment in addition to standard therapy may have a positive impact on patient survival, but further studies are needed to confirm these findings.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Public, Environmental & Occupational Health
Gilmar Reis et al.
Summary: Treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with early diagnosed COVID-19 reduced the need for hospitalisation defined as retention in a COVID-19 emergency setting or transfer to a tertiary hospital. The trial showed a higher probability of superiority (99.8%) surpassing the prespecified threshold of 97.6%.
LANCET GLOBAL HEALTH
(2022)
Letter
Medicine, General & Internal
Antonio Vitiello et al.
IRISH JOURNAL OF MEDICAL SCIENCE
(2021)
Article
Microbiology
Wendy P. Painter et al.
Summary: Molnupiravir showed rapid appearance and dose-proportional increase in plasma, with good tolerability in healthy volunteers. The study evaluated single and multiple doses of molnupiravir and the impact of food on pharmacokinetics in subjects, showing no accumulation following multiple doses and a decrease in absorption rate when administered with food, but no decrease in overall exposure.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Biochemistry & Molecular Biology
Wilfredo F. Garcia-Beltran et al.
Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.
Review
Biochemistry & Molecular Biology
Mohd Imran et al.
Summary: Molnupiravir, developed initially for influenza treatment, has shown promising activity against various viruses, including SARS-CoV-2. With good safety profile and oral bioavailability, it is currently in development for treating COVID-19 and expected to be available in an oral dosage form in 2022. Patent data suggests potential combinations with other drugs to enhance efficacy.
Editorial Material
Medicine, General & Internal
Athalia Christie et al.
Summary: The CDC recommends that fully vaccinated individuals can resume low-risk gatherings but should maintain public health measures in activities involving unvaccinated people.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Biochemistry & Molecular Biology
Constantinos Kurt Wibmer et al.
Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.
Article
Immunology
David Seftel et al.
Summary: In this study, 65 individuals opted to receive fluvoxamine for COVID-19 treatment, with a 0% hospitalization rate and 0% residual symptoms. In comparison, 48 individuals who chose observation alone had a hospitalization rate of 12.5% and residual symptoms in 60% of cases. This suggests that fluvoxamine may help alleviate the severity and duration of COVID-19.
OPEN FORUM INFECTIOUS DISEASES
(2021)
News Item
Medicine, General & Internal
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Review
Immunology
Nadim Sharif et al.
Summary: This study conducted a meta-analysis on the efficacy of COVID-19 vaccines, revealing that mRNA vaccines and adenovirus vector vaccines can provide moderate to high protection against COVID-19 in individuals aged 18 and above. However, evidence on the long-term protection of these vaccines in individuals under 16 years old against multiple variants of COVID-19 is limited.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Shuntai Zhou et al.
Summary: Mutagenic ribonucleosides can serve as broad-spectrum antiviral agents, but may pose risks to the host due to their host mutagenic activity in addition to antiviral activity.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Immunology
Giulia Rivasi et al.
Summary: This study found that COVID-19 vaccination led to a marked decline in infection rates among nursing home residents, with fully vaccinated individuals showing lower hospitalization and mortality rates compared to partially or unvaccinated individuals.
Review
Endocrinology & Metabolism
Awadhesh Kumar Singh et al.
Summary: Molnupiravir has shown significant benefits in reducing hospitalization or death in mild COVID-19 cases, making it a potential important tool in combating SARSCoV-2. However, its efficacy in moderate to severe COVID-19 remains uncertain, requiring further studies for clarification.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2021)
Article
Multidisciplinary Sciences
Kyle Rosenke et al.
Summary: Orally administered nucleoside analog MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model, with an inhibitory effect observed whether the drug is given 12 hours before or 12 hours after infection. This suggests the potential of MK-4482 for controlling SARS-CoV-2 infection in humans following high-risk exposure and for treating COVID-19 patients.
NATURE COMMUNICATIONS
(2021)
Article
Pharmacology & Pharmacy
Vikas P. Sukhatme et al.
Summary: Fluvoxamine, a well-tolerated and widely available selective serotonin reuptake inhibitor, has shown potential in preventing clinical deterioration of COVID-19 patients in a small study. It functions through various mechanisms such as antiviral effects, anti-inflammatory properties, and regulation of coagulopathy.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Immunology
Ali Pormohammad et al.
Summary: This study systematically reviewed the clinical features of COVID-19 vaccines in clinical trials, finding that mRNA-based and adenovirus-vectored vaccines exhibited different efficacy and side effect profiles. Both types of vaccines showed high efficacy after the first and second doses, with mRNA-based vaccines having higher reported side effects.
Article
Pharmacology & Pharmacy
Jianyuan Zhao et al.
Summary: Antiviral therapeutics are crucial in combating the COVID-19 pandemic, and a cell-based assay for SARS-CoV-2 RdRp has been developed to evaluate the efficacy of nucleotide analog inhibitors and their resistance to viral exoribonuclease-mediated proofreading. Molnupiravir and Remdesivir showed strong inhibition of SARS-CoV-2 RdRp, with Molnupiravir demonstrating the lowest EC50 value and Remdesivir having the highest resistance to exoribonuclease activity.
ANTIVIRAL RESEARCH
(2021)
Editorial Material
Pharmacology & Pharmacy
Antonio Vitiello et al.
DRUGS & THERAPY PERSPECTIVES
(2021)
Editorial Material
Biochemistry & Molecular Biology
Luis Menendez-Arias
Summary: Molnupiravir can be incorporated into viral RNA and used as template for RNA synthesis, leading to error catastrophe in SARS-CoV-2.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2021)
Article
Biochemistry & Molecular Biology
Florian Kabinger et al.
Summary: Molnupiravir is an oral antiviral drug candidate that increases viral RNA mutations frequency and inhibits replication of SARS-CoV-2 by altering the substrate preference of RdRp. This two-step mutagenesis mechanism can explain the broad-spectrum antiviral activity of molnupiravir, making it a promising COVID-19 treatment option.
NATURE STRUCTURAL & MOLECULAR BIOLOGY
(2021)
Article
Cell Biology
Timothy P. Sheahan et al.
SCIENCE TRANSLATIONAL MEDICINE
(2020)
Article
Medical Laboratory Technology
Mart Toots et al.
TRANSLATIONAL RESEARCH
(2020)
Editorial Material
Medicine, General & Internal
Robin E. Ferner et al.
BMJ-BRITISH MEDICAL JOURNAL
(2020)
Article
Medicine, General & Internal
Eric J. Lenze et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2020)
Article
Virology
Maria L. Agostini et al.
JOURNAL OF VIROLOGY
(2019)
